News Release today:
Houston, TX, July 16, 1996 -- ImmuDyne, Inc. (symbol IMMD) announced $2,441,837 in sales for the first three quarters
ending May 31, 1996. This is a 33% increase in sales over the same period of the prior year of $1,838,131. Sales for the first
nine months of 1996 exceed annual sales for 1995 of $2,241,088. A loss of $245,930 was recorded for the third quarter ending
May 31, 1996, due to continuing legal expenses and investment in advertising and promotion of the new products. On a
year-to-date basis, there is an improvement of $222,119 or 33% reduction in loss, from the same period in the prior year. Upon
termination of the Company's litigation related expenses, which account for the majority of the loss, and with minimal sales from
the new marketing divisions, the Company is expected to become profitable.
ImmuDyne, Inc. has developed three completely new marketing divisions within the last six months; Human Nutrition,
Companion Animal Health and Nutrition, and Aquaculture. It is anticipated that the Human Nutrition Division will be profitable
for the month of July. Each division is set up independently to pursue distinct applications of ImmuDyne's unique technology.
"ImmuDyne's new divisions are very much 'on track', with many opportunities for growth and partnerships in their industries,"
remarked President James D. Wood.
ImmuDyne Inc. is listed on the NASD Automated Bulletin Board under the symbol IMMD.
ImmuDyne, Inc. is a Texas-based biotechnology company specializing in macrophage technology. It has patented Immune
Stimulation or Biological Response Modification technology relating to immune system stimulants for pharmaceutical, cosmetic,
nutritional, veterinary and agricultural use. ImmuDyne, Inc., maintains offices in Houston, Texas and Palo Alto, California. For
additional information, contact Margaret Dreyfus, Investor Relations, at (415) 949-3864. |
